These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8093421)

  • 1. Movement disorders: therapeutic role of vitamin E.
    Cadet JL
    Toxicol Ind Health; 1993; 9(1-2):337-47. PubMed ID: 8093421
    [No Abstract]   [Full Text] [Related]  

  • 2. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E.
    Cadet JL; Lohr JB
    Ann N Y Acad Sci; 1989; 570():176-85. PubMed ID: 2576510
    [No Abstract]   [Full Text] [Related]  

  • 3. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
    Lohr JB; Caligiuri MP
    J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 5. Sodium valproate and biperiden in neuroleptic-induced akathisia, parkinsonism and hyperkinesia. A double-blind cross-over study with placebo.
    Friis T; Christensen TR; Gerlach J
    Acta Psychiatr Scand; 1983 Mar; 67(3):178-87. PubMed ID: 6134430
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapeutic trial of tiapride in extrapyramidal syndromes caused by neuroleptics].
    Zarranz JJ; Caso C; Blanco J
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1980; 8(6):503-8. PubMed ID: 6110319
    [No Abstract]   [Full Text] [Related]  

  • 7. Tamoxifen effect on L-DOPA induced response complications in parkinsonian rats and primates.
    Smith CP; Oh JD; Bibbiani F; Collins MA; Avila I; Chase TN
    Neuropharmacology; 2007 Feb; 52(2):515-26. PubMed ID: 17116309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E.
    Elkashef AM; Wyatt RJ
    Schizophr Bull; 1999; 25(4):731-40. PubMed ID: 10667743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Parkinsonism and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (review of the literature)].
    Atadzhanov MA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1991; 91(4):117-21. PubMed ID: 1650080
    [No Abstract]   [Full Text] [Related]  

  • 10. Vitamin E in the treatment of tardive dyskinesia.
    Elkashef AM; Ruskin PE; Bacher N; Barrett D
    Am J Psychiatry; 1990 Apr; 147(4):505-6. PubMed ID: 1969247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol for tardive dyskinesia and extrapyramidal side effects (pseudoparkinsonism) from neuroleptics.
    Kulik FA; Wilbur R
    Psychopharmacol Bull; 1980 Jul; 16(3):18-9. PubMed ID: 6105690
    [No Abstract]   [Full Text] [Related]  

  • 12. Vitamin E treatment of tardive dyskinesia.
    Adler LA; Peselow E; Rotrosen J; Duncan E; Lee M; Rosenthal M; Angrist B
    Am J Psychiatry; 1993 Sep; 150(9):1405-7. PubMed ID: 8102511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.
    Shriqui CL; Bradwejn J; Annable L; Jones BD
    Am J Psychiatry; 1992 Mar; 149(3):391-3. PubMed ID: 1346951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tardive dyskinesia and antiparkinsonian medication.
    Chouinard G; De Montigny C; Annable L
    Am J Psychiatry; 1979 Feb; 136(2):228-9. PubMed ID: 32778
    [No Abstract]   [Full Text] [Related]  

  • 15. Modeling dyskinesia in animal models of Parkinson disease.
    Morin N; Jourdain VA; Di Paolo T
    Exp Neurol; 2014 Jun; 256():105-16. PubMed ID: 23360802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
    Wirshing WC; Freidenberg DL; Cummings JL; Bartzokis G
    J Clin Psychopharmacol; 1989 Dec; 9(6):407-11. PubMed ID: 2574192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neuroleptic parkinsonism and tardive dyskinesia and methods of pharmacologically correcting these pathologic conditions (review)].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(2):269-77. PubMed ID: 2858951
    [No Abstract]   [Full Text] [Related]  

  • 18. Alessandro Agnoli Lecture. Models of basal ganglia dysfunction: predictions and pitfalls.
    Albin RL; Kearney JA
    Funct Neurol; 2000; 15(3):135-46. PubMed ID: 11062842
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
    J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism.
    Noring U; Povlsen UJ; Casey DE; Gerlach J
    Psychopharmacology (Berl); 1984; 84(4):569-71. PubMed ID: 6152058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.